Hims & Hers is executing a high-stakes strategic pivot toward compounded GLP-1 offerings, evidenced by a 38.2% YoY revenue surge to $753.2M in 2026Q2, but this shift has compressed gross margins to 63.8% and swung operating income to a -$97.2M loss. The compan...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue accelerated 38.2% YoY to $753.2M in 2026Q2, but gross margin compressed to 63.8% from 73.8% a year earlier, and operating income swung to a -$97.2M loss as SG&A consumed 56.8% of revenue.
Hims & Hers provides 100% online access to expert-backed healthcare services, including weight loss care, ED treatment, and lab testing.
The company offers personalized health solutions for men, including medical consultations, prescriptions, and delivery, enhancing user experience.
Hims & Hers has demonstrated breakout performance with triple-digit growth, driven by rising personalized offerings and disciplined execution.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.37-643.1% vs -$0.05 | $753M+7.8% vs $699M |
Q2 2026 May 11, 2026 | -$0.40-1676.7% vs $0.03 | $608M-1.4% vs $617M |
Q1 2026 Feb 23, 2026 | $0.07+250.0% vs $0.02 | $618M-0.2% vs $619M |
Q4 2025 Nov 3, 2025 | $0.06-33.3% vs $0.09 | $599M-3.1% vs $618M |
If you purchased or acquired Hims securities between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.
Benchmark HIMS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Hims & Hers Health, Inc. (HIMS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.39 | $6.33B | 55.67 | 59% | 5.47% | 25.23% | — | |
| $6.13 | $1.11B | -5.38 | -1.54% | -7.13% | -13.08% | — | |
| $26.57 | $4.97B | 27.11 | 13.05% | 25.48% | 16.95% | — | |
| $7.60 | $142.61M | 28.15 | 18.78% | 4.66% | 3.6% | — | |
| $229.94 | $165.69B | 165.42 | 35.82% | 10.67% | 3.08% | — | |
| $38.17 | $169.5B | 10.91 | 6.43% | 35.35% | 59.09% | — |
Hims & Hers Health, Inc. (HIMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Hims & Hers Health, Inc. (HIMS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jul 17, 2026·SEC
Jul 1, 2026·SEC
Feb 23, 2026·SEC
Get notified when HIMS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Hims & Hers Health, Inc. (HIMS) stock FAQ — growth, dividends, profitability & financials explained
Hims & Hers Health, Inc. (HIMS) reported $2.58B in revenue for fiscal year 2025. This represents a 3023% increase from $82.6M in 2019.
Hims & Hers Health, Inc. (HIMS) grew revenue by 59.0% over the past year. This is strong growth.
Hims & Hers Health, Inc. (HIMS) reported a net loss of $142.0M for fiscal year 2025.
Hims & Hers Health, Inc. (HIMS) has a return on equity (ROE) of 25.2%. This is excellent, indicating efficient use of shareholder capital.
Hims & Hers Health, Inc. (HIMS) generated $89.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
